

Recurrence in Whipple's disease. Response to a reply[☆]

La recurrencia en la enfermedad de Whipple. Contestación a réplica

Dear Editor:

We read with considerable interest the reply and manuscript on Whipple's disease (WD) published by Benito-León et al. and cited in the reference section of our letter.^{1,2} We would like to thank these authors for their input. They emphasise the isolated presentation in the central nervous system and the relapsing-recurring course that may characterise Whipple's disease with neurological involvement. We agree that when WD presents as isolated encephalitis, diagnosis is difficult due to symptoms being polymorphic. Of all the symptoms, the one most suggestive of WD is oculomastatory myorhythmia. However, the presence of any of the listed disorders due to an unknown cause requires an examination to rule out or confirm WD. As our colleagues rightly point out, there is a specific treatment for WD that can resolve all of its symptoms. Although it is a bacterial infection, the best way of curing it is still being researched, and relapses do occur. Benito-León indicates that with early diagnosis, sequelae and deterioration will be much more controllable. We could not agree more with that statement. In the case we presented, a diagnosis of WD was finally established for a patient who had been suffering from multiple recurrences and systemic remissions for 20 years.³ With better understanding and exchange of information, underdiagnosis of WD will become less common.

Why do recurrences appear, and what areas are being researched?

One line of research focuses on the analysis of *Tropheryma whippelii* (TW) bacteria. A group of specialists from different European countries researched the bacterial genotype in 39 patients with WD and in 10 healthy carriers. The digestive tract was infected in 25 patients, and 3 of those patients suffered from relapses with nervous system involvement. There were no digestive symptoms in 7 patients; 5 cases had endocarditis; 1 had spondylodiscitis; and 1 had isolated neurological infection. These observations reveal

that TW DNA has a high level of genetic variability and is not correlated with the array of affected organs, relapse severity, or the bacterial pathogenesis, even when we include the carrier group.⁴

The second hypothesis has to do with a host's inability to control an infection. In a study of 145 patients with WD and 166 controls, Moos et al. analysed the behaviour of macrophages and lymphocytes. They concluded that macrophages in ill patients were incompetent to degrade TW.⁵ Other publications on macrophage inefficiency in the immune system have already been mentioned.

Numerous recurrences were observed in our patient, most of which coincided with decreases in dosage or discontinuation of the antibiotic during the very long follow-up time. We therefore concur with Benito-León; it is best to continue antibiotic treatment during an extended period of time to avoid relapses, until such time as we dispose of strategies for controlling abnormal macrophage function in the host.

References

1. Benito-León J, Arpa J, Louis ED, Herrera I, De La Loma A. Isolated CNS Whipple disease: acute onset and relapsing-remitting course. *Scand J Infect Dis.* 2007;39:623–5.
2. Benito-León J, Sedano LF, Louis ED. Isolated central nervous system Whipple's disease causing reversible frontotemporal-like dementia. *Clin Neurol Neurosurg.* 2008;110:747–9.
3. Domínguez RO, Müller C, Davolos I, MacKeith P, Arias E, Taratuto AL. Enfermedad de Whipple: múltiples recaídas sistémicas y neurológicas. *Neurología* 2011, doi:10.1016/j.nrl. 2011.04.009.
4. Li W, Fenollar F, Rolain JM, Fournier PE, Feurle GE, Müller C, et al. Genotyping reveals a wide heterogeneity of *Tropheryma whippelii*. *Microbiology.* 2008;154:521–7.
5. Moos V, Schmidt C, Geelhaar A, Kunkel D, Allers K, Schinnerling K, et al. Impaired immune functions of monocytes and macrophages in Whipple's disease. *Gastroenterology.* 2010;138:210–20.

R.O. Domínguez^{a,*}, I. Davolos^b

^a *Departamentos de Neurología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina*

^b *Medicina Interna, Hospital Sirio Libanés, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina*

* Corresponding author.

E-mail address: dominguezraulo@yahoo.com.ar (R.O. Domínguez).

[☆] Please cite this article as: Domínguez RO, Davolos I. La recurrencia en la enfermedad de Whipple. Contestación a réplica. *Neurología.* 2012;27:377.

Cerebral death is not a synonym of whole brain death[☆]

Muerte cerebral no es un término sinónimo de muerte encefálica

Dear Editor:

It was with great interest that we read the original article by Iriarte et al.¹ regarding university students' concepts of

death defined according to neurological criteria. We agree with the authors' view that both health professionals and society at large should possess a basic knowledge of these concepts, and the medical and legal implications which they entail. However, we would like to call attention to the term 'muerte cerebral' or 'cerebral death' which the authors use throughout the manuscript. It is true that there is a lack of uniformity among the different definitions of brain death. It is also true that while firmly established standards for diagnosing brain death do exist, the standards vary greatly

[☆] Please cite this article as: Egea-Guerrero JJ, et al. Muerte cerebral no es un término sinónimo de muerte encefálica. *Neurología.* 2012;27:377–8.

from country to country.^{2–5} Some of the confusion arises from the way the term 'brain death', as defined by the Harvard criteria published in 1968, has been translated in Spanish.⁶ We are fully aware of the neuroanatomical differences between whole brain death, brainstem death, and neocortical or cerebral death. The first two definitions of death (based on neurological criteria) are the most widespread, and also the most polemic.^{7–9} All of these definitions revolve around what they consider to be the 'brain' in 'brain death'. On this topic, Spanish law as cited by Iriarte et al. clearly establishes that death must be diagnosed and certified based on "irreversible cessation of cardiopulmonary functions or brain functions".¹⁰ For this reason, we feel that using 'cerebral death' as a synonym for whole brain death is confusing to both health care professionals and society at large. We understand that '*muerte cerebral*' or 'cerebral death' is widely used by Spanish speakers, but the term should not be employed in medicine. If the concepts employed in our definitions are inappropriately explained, the definitions themselves are more likely to be misunderstood.

References

1. Iriarte J, Palma JA, Kufof E, De Miguel MJ. Muerte cerebral: ¿es un término adecuado? *Neurología*. 2012;27:16–21.
2. Haupt WF, Rudolf J. European brain death codes: a comparison of national guidelines. *J Neurol*. 1999;236:432–7.
3. Greer DM, Varelas PN, Haque S, Wijdicks EF. Variability of brain death determination guidelines in leading US neurologic institutions. *Neurology*. 2008;22:284–9.
4. Egea-Guerrero JJ, Illescas-Vacas A, Juan-Díaz M, Revuelto-Rey J, Serrano-Lázaro A, Domínguez-Roldán J. Brain death. Diferencias en el concepto de muerte encefálica con el Reino Unido. In: Perez-Bernal J, editor. *Actualizaciones en trasplantes 2009*. 1st ed. Sevilla: Hospitales Universitarios Virgen del Rocío; 2009. p. 101–4.
5. Capron AM. Brain death — well settled yet still unresolved. *N Engl J Med*. 2001;344:1244–6.
6. A definition of irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical School to examine the definition of brain death. *JAMA*. 1968;205:337–40.
7. Mohandas A, Chou SN. Brain death: a clinical and pathological study. *J Neurosurg*. 1971;35:211–8.
8. Machado-Curbelo C. ¿Defendemos una visión encefálica de la muerte? *Rev Neurol*. 2002;35:387–96.
9. Bell MD, Moss E, Murphy PG. Brainstem death testing in the UK-time for reappraisal? *Br J Anaesth*. 2004;92:633–40.
10. Boletín Oficial del Estado de España, BOE 4 de enero de 2000. Ministerio de la Presidencia. Real Decreto 2070/1999.

J.J. Egea-Guerrero*, J. Revuelto-Rey, E. Gordillo-Escobar

Unidad de Neurocríticos, Unidad de Gestión Clínica de Cuidados Críticos y Urgencias, Hospital Universitario Virgen del Rocío, Sevilla, Spain

*Corresponding author.

E-mail address: juanjoegea@hotmail.com (J.J. Egea-Guerrero).

Recurrent reversible posterior encephalopathy syndrome with a response to nimodipine[☆]

Síndrome de encefalopatía posterior reversible recurrente con respuesta a nimodipino

Dear Editor:

Posterior reversible encephalopathy syndrome (PRES) is the association of a set of clinical characteristics (headache, epileptic seizures, changes in alertness, visual loss and other focal deficits) and radiological signs indicating reversible changes in white matter, especially in the parietal-temporal-occipital area.^{1,2} It has been linked to high blood pressure and immunosuppressive agents, among other factors. Recurrence is infrequent; a recent study of 25 patients with

long-term follow-up³ reported it in 8% of the study cases.

Various physiopathological mechanisms have been suggested, including vasoconstriction, increased perfusion, and endothelial damage. A study of recurrent cases may help us answer some of the unresolved questions about this syndrome. We present the case of a patient with recurrent PRES episodes which were effectively treated with nimodipine. The patient was a 60-year-old female who came to the emergency department in May 2009. She had a history of smoking, high blood pressure, high cholesterol, and ischaemic heart disease. She presented with headache, drowsiness, nausea, vomiting, and aphasic comprehension which had developed over 2 days, coinciding with an attack of hypertension (blood pressure 220/110 mm Hg). Once the hypertension had been resolved, the patient gradually regained her baseline state and was asymptomatic 48 to 72 hours after being admitted. The patient had been treated with chemotherapy during the preceding 2 years for stage IV ovarian adenocarcinoma. Magnetic resonance (MR) scan showed predominantly parietal-occipital white matter lesions with no restrictions in the diffusion sequences. The lesions disappeared one month later (Fig. 1). Following that, the patient presented with 3 similar episodes in January, April, and June 2010; all episodes coincided with a marked increase in blood

[☆] Please cite this article as: Matías-Guiú JA, et al. Síndrome de encefalopatía posterior reversible recurrente con respuesta a nimodipino. *Neurología*. 2012;27:378–80.